1. ALCARAZ, ALLEGRE, ALMORA, ALONZO, AMARO, AMOLENDA, ANACTA, ANDAL, ANG, J.

2. General Data A.T., 78 y.o., female Pertinent data that should have been asked: – Occupation

3. Chronic cough

4. History Of Present Illness 6 months PTA non-productive cough no consultation 2 months PTA cough, becoming productive low grade fever loss of appetite 2 weeks PTA productive cough low grade fever dyspnea weight loss ADMISSION

5. History Of Present Illness Pertinent data that should have been asked: – Timing Onset, duration, frequency – Character Severity – Associated events or accompanying symptoms – Relieving and aggravating factors – Quantify weight loss

6. Past Medical History No previous surgeries No allergies Non-hypertensive Non-diabetic (+) COPD Pertinent data that should have been asked: – Date of diagnosis of COPD

7. Family History (-) Diabetes (-) Hypertension/Heart disease (-) Asthma/Allergies (+) COPD Pertinent data that should have been asked: – Family history of cancer or malignancies – Exposure to TB

8. Personal/Social History 30 pack year smoking history Occasional alcoholic beverage drinker Pertinent data that should have been asked: – Diet and exercise – Environmental data (living condition)

9. Review Of Systems No weakness No headache No cyanosis No edema (+) Fatigue (+) Dyspnea (+) Occasional chest pain

10. Physical Examination Vital Signs: BP= 120/80 PR = 100bpm RR= 24cpm Temp= 37.5°C

11. Physical Examination Conscious, coherent, ambulatory Pink palpebral conjunctiva, anicteric sclera Moist buccal mucosa, non hyperemic PPW Supple neck, no palpable cervical lymph nodes Adynamic precordium, apex beat 5 th LICS MCL, no murmurs Symmetrical chest expansion, no retractions, (+) occasional wheeze, RUL Flat abdomen, NABS, soft, non tender No cyanosis, pulses full and equal

12. Salient Features Subjective 78 y.o., female Chronic cough (productive) Occasional chest pain Dyspnea Low grade fever Fatigue Weight loss COPD 30 pack year smoking Objective Tachypnea (RR=24cpm) Fever (37.5°C) Occasional wheeze, RUL

13. TREATMENT

14. General Measures Treatment is determined by the extent of the spread Surgery to remove all of the lung (pneumonectomy) or part of the lung (lobectomy) may be recommended if cancer is at an early stage Treatment options depend upon TNM staging Radiation may be recommended

15. Medications Chemotherapy with multiple drugs, cisplatin and topoisomerase inhibitors (with or without radiation therapy), has yielded higher survival rates than surgery particularly in patients with small cell carcinoma – Some improved results with drugs have been reported, but studies to determine the most effective chemotherapeutic combination are ongoing Pain killers (narcotic analgesics) for palliation

16. Palliative Treatments May involve radiation therapy and is geared toward alleviating symptoms Research about alternative therapies, such as vaccines and immunotherapy, are currently in progress

17. Non-Small Cell Lung Cancer Surgery offers the best chance for curing and is recommended if the patient is a viable candidate – Only 25% of lung cancer patients are considered to be surgical candidates at the time of diagnosis Radiation controls local disease and is most commonly used to palliate symptoms – 10-20% of localized disease can be cured

18. Non-Small Cell Lung Cancer Chemotherapy and/or radiation therapy may be considered after surgery for cancer that has progressed to advanced stages – Radiation plus Cisplatin-based chemotherapy are recommended if the patient is not a surgical candidate

19. Small Cell Carcinoma Chemoterapy is the cornerstone of treatement – Regimens containing etoposide and either carboplatin or cisplatin is belived to offer the best combination of efficacy and lack of toxicity Surgery is not considered helpful because small cell carcinoma has usually spread at the time of diagnosis

20. PROGNOSIS

21. Prognosis Without surgery, this condition is currently considered incurable, early diagnosis is critical – If lung cancer is caught in its early stages, the survival rate is approximately 50% Recurrence is common The five-year survival rate for all diagnosed lung cancers is 10-15%

22. References http://www.ecureme.com/emyhealth/data/Br onchogenic_Carcinoma.asp http://www.ecureme.com/emyhealth/data/Br onchogenic_Carcinoma.asp http://www.rxmed.com/b.main/b1.illness/b1. 1.illnesses/Bronchogenic%20Carcinoma.html http://www.rxmed.com/b.main/b1.illness/b1. 1.illnesses/Bronchogenic%20Carcinoma.html http://www.medstudents.com.br/pneumo/pn eumo7/pneumo7.htm http://www.medstudents.com.br/pneumo/pn eumo7/pneumo7.htm